Study on the network pharmacology of Scutellariae Radix in the treatment of hypertension
DONG Mingyue1 HUANG Yan2 ZHOU Lihua2▲
1.The Third Clinical Medical College, He’nan University of Chinese Medicine, He’nan Province, Zhengzhou 450000, China; 2
.Traditional Chinese Medicine Clinic, the Third Affiliated Hospital of He’nan University of Chinese Medicine, He’nan Province, Zhengzhou 450000, China
Abstract:Objective To analyze the potential mechanism of Scutellariae Radix in the treatment of hypertension through network pharmacology. Methods The traditional Chinese medicine systems pharmacology database and analysis platform (TCMSP) was used to screen the chemical components and targets of Scutellariae Radix; GeneCards, OMIM, TTD, and DrugBank databases were used to screen out the disease targets of hypertension; Cytoscape 3.7.2 software was used to construct the “active component-disease target” network of Scutellariae Radix in the treatment of hypertension. The protein-protein interaction (PPI) network was constructed with the help of String database; finally, the R language was used to perform GO annotation analysis and KEGG pathway analysis on the target. Results A total of 86 targets of interaction between Scutellariae Radix and hypertension were identified, among which, CCND1, CDKN1A, ESR1, and others were the core genes. GO functional enrichment mainly included cell response to chemical stress, oxidative stress and adrenergic receptor activity. Among the KEGG pathways, Kaposi sarcoma associated herpesvirus infection, human cytomegalovirus infection and PI3K-Akt signaling pathway were the most significant. Conclusion Thirty-one active components of Scutellariae Radix act on 86 targets to reduce blood pressure, which reflects the characteristics of Scutellariae Radix in the treatment of hypertension through multi-component, multi-target and multi-channel.
董明月1 黄艳2 周立华2▲. 黄芩治疗高血压的网络药理学研究[J]. 中国医药导报, 2021, 18(12): 15-19.
DONG Mingyue1 HUANG Yan2 ZHOU Lihua2▲. Study on the network pharmacology of Scutellariae Radix in the treatment of hypertension. 中国医药导报, 2021, 18(12): 15-19.